Print
Email
Print Edition StoriesMonday, December 21, 2009
Organogenesis seeks FDA nod for human cell-based tech
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Researchers focus on macular degeneration
Tissue therapy company Organogenesis Inc. has sent its CelTx product, intended for gum regeneration, to the U.S. Food and Drug Administration with a Premarket Approval Application filing. It would mark the first “living cell-based technology” approved for the dental market.
The Canton-based company first tested CelTx, which contains living human cells in a collagen matrix, in clinical trials for gingival recession, the loss of a seal around teeth, bone and ligaments, which can lead to tooth decay or tooth loss.
CelTx, if approved, would eliminate the need for current gingival recession treatments, including palate grafts, which transplant tissue from one part of the mouth to another and usually leads to pain and an unmatched appearance of the gums.
More about Organogenesis
In January, the Massachusetts Life Sciences Center announced it would provide a $7.4 million grant to Organogenesis to expand the company’s facilities and accommodate its forecasted job growth. Company officials said it plans to become the “largest cell therapy manufacturing facility in the world.”
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
